QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of its QIAGEN Clinical Insight® (QCI™) bioinformatics content and software platform for clinical testing labs to interpret and report on genomic variants identified in next-generation sequencing (NGS). The first two supported applications for the bioinformatics platform are in oncology, for somatic and hereditary cancer testing. QIAGEN will demonstrate the QCI software at the upcoming ClinGen/DECIPHER Meeting (May 27-28, Washington D.C.), ASCO Annual Meeting (May 29-June 2, Chicago), and European Society of Human Genetics Conference (June 6-9, Glasgow).
{iframe}http://www.prnewswire.com/news-releases/qiagen-launches-clinical-bioinformatics-platform-for-next-generation-sequencing-505059521.html{/iframe}